The expert review of the "2022 National Medical Insurance Drug Catalogue" has ended, and the national talks are about to start (with list)

In accordance with the Work Plan for the Adjustment of the Drug Catalogue of the National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance in 2022, the National Medical Insurance Bureau organized experts to conduct a comprehensive review
of the declared drugs that passed the review of the adjustment form of the National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Drug Catalogue in 2022 (hereinafter referred to as the 2022 National Medical Insurance Drug Catalogue).
At present, the expert review work has been completed, and the announcement is as follows:

1.
All reporting enterprises can log on to the "2022 National Medical Insurance Drug Catalogue Adjustment and Declaration" module of the National Medical Insurance Service Platform (fuwu.
nhsa.
gov.
cn) (hereinafter referred to as the declaration module) to query the expert review results
.

2.
For drugs whose evaluation result is "new to be added for negotiation", "new to be added to bid", "to be renewed through negotiation", and "to be simplified renewal", the corresponding enterprise will download the corresponding "confirmation letter template" in the "
declaration module".
Please fill in and affix the official seal as required and upload it to the "Declaration Module" before 17:00 on October 20, 2022, and send the original to the National Health Insurance Bureau (subject to the postmark).

3.
To confirm the participation in the negotiation and confirm the drug participating in the bidding, the corresponding enterprise downloads the corresponding "submission material template" in the "declaration module", and fills in and submits
it as required.
Enterprises should ensure that the relevant data and materials submitted are complete, true and reliable, and send one copy of the paper version and one copy of the electronic CD-ROM (the first volume of materials are available in both Word and PDF) to the National Health Insurance Bureau (subject to the postmark)
before 17:00 on November 3, 2022.

Please click "Details" in the "Negotiation/Bidding Information" column to view
the contents of the negotiation/bidding reference drugs, main specifications of the negotiation, and medical insurance payment scope determined by the expert review.

4.
If the evaluation result is "new to be added for negotiation" or "new to be added to bid", it means that the drug has been included in the negotiation/bidding scope of the 2022 national medical insurance drug catalogue and has obtained the negotiation/bidding qualification, which does not mean that the drug has been included in the 2022 national medical insurance drug catalogue
.

5.
In order to ensure the smooth progress of the subsequent stage of the catalogue adjustment, before the official release of the national medical insurance drug catalogue in 2022, all reporting enterprises should not release any information
of this adjustment.

Tel: 010-89061448/1449 (October 17, 2022 - November 3, 2022, working days 9:00-17:00)

Email: YBML001@nhsa.
gov.
cn (email named "Company Name" + "Drug Name")

Mailing address: No.
2-9, Yuetan North Street, Xicheng District, Beijing National Medical Security Administration Medical Insurance Directory Adjustment Working Group 100830